U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C10H15NO3
Molecular Weight 197.231
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METANEPHRINE, (+/-)

SMILES

CNCC(O)C1=CC(OC)=C(O)C=C1

InChI

InChIKey=JWJCTZKFYGDABJ-UHFFFAOYSA-N
InChI=1S/C10H15NO3/c1-11-6-9(13)7-3-4-8(12)10(5-7)14-2/h3-5,9,11-13H,6H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C10H15NO3
Molecular Weight 197.231
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Metanephrine (metadrenaline) is a metabolite of epinephrine (adrenaline) created by the action of catechol-O-methyl transferase on epinephrine. It is a commonly occurring, pharmacologically and physiologically inactive metabolite of epinephrine. The measurement of plasma free metanephrines is considered to be the best tool in the diagnosis of pheochromocytoma, a rare kind of adrenal medullary neoplasm. In adrenal chromaffin cells, leakage of norepinephrine and epinephrine from storage granules leads to the substantial intracellular production of the O-methylated metabolite metanephrine. In fact, the adrenals constitute the single largest source out of any organ system including the liver for circulating metanephrine. In humans, about 93 percent of circulating metanephrine is derived from catecholamines metabolized within adrenal chromaffin cells.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
34.2 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Unknown
Diagnostic
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Dogs were treated with metanephrine i.v. at a rate of 50mkg/kg/min for a 10-min period and then at a rate of 20mkg/kg/min for
Route of Administration: Intravenous
In Vitro Use Guide
Caki-1 cells were preincubated at 37°C for 20 min in buffer A (125 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, 5.6 mM D-(+)-glucose, 1 mM L-(+)-ascorbic acid; pH 7.4). Subsequently, cells were incubated at 37°C with 300 μl buffer A containing 200 nM [3H]MPP+. Incubation was stopped by rinsing the cells with 300 μl ice-cold buffer A. The cells were then solubilized with 0.1% (v/v) Triton X-100 (in 5 mM Tris-HCl, pH 7.4), and placed at 37°C overnight. When used, inhibitors of transport (Metanephrine) were present during both the preincubation and incubation periods. Radioactivity was measured by liquid scintillation counting.
Substance Class Chemical
Record UNII
1ZE0530JEJ
Record Status Validated (UNII)
Record Version